Humira

CONTENTS

5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Humira : Crohn’s disease
26 Humira : Axial spondyloarthritis (axSpA)
41 Humira : Rheumatoid arthritis (RA)
53 Humira : Psoriatic arthritis (PsA)
66 Humira : Ulcerative colitis
79 Humira : Psoriasis

LIST OF FIGURES
16 Figure 1: Humira for Crohn’s disease – SWOT analysis
17 Figure 2: Datamonitor Healthcare’s drug assessment summary of Humira in Crohn’s disease
18 Figure 3: Datamonitor Healthcare’s drug assessment summary of Humira in Crohn’s disease
22 Figure 4: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
32 Figure 5: Humira for axial spondyloarthritis – SWOT analysis
33 Figure 6: Datamonitor Healthcare’s drug assessment summary of Humira in axial spondyloarthritis
34 Figure 7: Datamonitor Healthcare’s drug assessment summary of Humira in axial spondyloarthritis
37 Figure 8: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016–25
48 Figure 9: Humira for rheumatoid arthritis – SWOT analysis
49 Figure 10: Datamonitor Healthcare’s drug assessment summary of Humira in rheumatoid arthritis
50 Figure 11: Datamonitor Healthcare’s drug assessment summary of Humira in rheumatoid arthritis
60 Figure 12: Humira for psoriatic arthritis – SWOT analysis
61 Figure 13: Datamonitor Healthcare’s drug assessment summary of Humira for psoriatic arthritis
62 Figure 14: Datamonitor Healthcare’s drug assessment summary of Humira for psoriatic arthritis
73 Figure 15: Humira for ulcerative colitis – SWOT analysis
74 Figure 16: Datamonitor Healthcare’s drug assessment summary of Humira for ulcerative colitis
75 Figure 17: Datamonitor Healthcare’s drug assessment summary of Humira for ulcerative colitis
88 Figure 18: Humira for psoriasis – SWOT analysis
89 Figure 19: Datamonitor Healthcare’s drug assessment summary of Humira in psoriasis
90 Figure 20: Datamonitor Healthcare’s drug assessment summary of Humira in psoriasis

LIST OF TABLES
6 Table 1: Humira drug profile
8 Table 2: Humira pivotal trial data in adult Crohn’s disease
12 Table 3: Humira pivotal trial data in pediatric Crohn’s disease
15 Table 4: Humira ongoing trials in Crohn’s disease
23 Table 5: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
26 Table 6: Humira drug profile
28 Table 7: Humira pivotal trial data in axial spondyloarthritis
31 Table 8: Humira late-phase trial data in axial spondyloarthritis
38 Table 9: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016–25
42 Table 10: Humira drug profile
44 Table 11: Humira pivotal trial data in rheumatoid arthritis
46 Table 12: Humira late-phase trial data in rheumatoid arthritis
54 Table 13: Humira drug profile
56 Table 14: Humira pivotal trial data in psoriatic arthritis
59 Table 15: Humira late-phase trial data in psoriatic arthritis
67 Table 16: Humira drug profile
69 Table 17: Humira pivotal trial data in ulcerative colitis
72 Table 18: Humira ongoing late-phase trials in ulcerative colitis
80 Table 19: Humira drug profile
82 Table 20: Humira pivotal trial data in adult psoriasis
83 Table 21: Humira pivotal trial data in pediatric psoriasis
84 Table 22: Humira late-phase trial data in psoriasis
87 Table 23: Humira ongoing late-phase clinical trials in psoriasis